Which has preferable valuation and earnings, PMVP or NXTC?

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PMV Pharmaceuticals N/A N/A -$77.74M -$1.42 N/A NextCure N/A N/A -$55.84M -$8.70 N/A

Is PMVP or NXTC more profitable?

PMV Pharmaceuticals' return on equity of -78.11% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets PMV Pharmaceuticals N/A -78.11% -70.13% NextCure N/A -154.62% -100.19%

Does the media favor PMVP or NXTC?

In the previous week, PMV Pharmaceuticals had 1 more articles in the media than NextCure. MarketBeat recorded 2 mentions for PMV Pharmaceuticals and 1 mentions for NextCure. PMV Pharmaceuticals' average media sentiment score of 0.51 beat NextCure's score of 0.00 indicating that PMV Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PMV Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NextCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, OKYO or NXTC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$8.95M N/A N/A NextCure N/A N/A -$55.84M -$8.70 N/A

Is OKYO or NXTC more profitable?

OKYO Pharma's return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A NextCure N/A -154.62% -100.19%

Does the media prefer OKYO or NXTC?

In the previous week, OKYO Pharma had 1 more articles in the media than NextCure. MarketBeat recorded 2 mentions for OKYO Pharma and 1 mentions for NextCure. OKYO Pharma's average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OKYO Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NextCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GOSS or NXTC more profitable?

NextCure has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Gossamer Bio -235.00% N/A -112.04% NextCure N/A -154.62% -100.19%

Does the media favor GOSS or NXTC?

In the previous week, Gossamer Bio had 3 more articles in the media than NextCure. MarketBeat recorded 4 mentions for Gossamer Bio and 1 mentions for NextCure. Gossamer Bio's average media sentiment score of 0.63 beat NextCure's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NextCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate APLM or NXTC?

NextCure has a consensus price target of $19.00, suggesting a potential upside of 273.28%. Given NextCure's stronger consensus rating and higher possible upside, analysts clearly believe NextCure is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger earnings and valuation, APLM or NXTC?

Apollomics has higher revenue and earnings than NextCure. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 8.10 -$10.94M N/A N/A NextCure N/A N/A -$55.84M -$8.70 N/A

Is APLM or NXTC more profitable?

Apollomics' return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A NextCure N/A -154.62% -100.19%

Is CNTB or NXTC more profitable?

NextCure's return on equity of -154.62% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -165.41% -121.58% NextCure N/A -154.62% -100.19%

Does the media favor CNTB or NXTC?

In the previous week, Connect Biopharma had 17 more articles in the media than NextCure. MarketBeat recorded 18 mentions for Connect Biopharma and 1 mentions for NextCure. Connect Biopharma's average media sentiment score of 0.19 beat NextCure's score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 5 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral NextCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NextCure (NXTC) Competitors

$5.00 -0.09 (-1.77%)

As of 01:33 PM Eastern

Compare

NXTC vs. PMVP, OKYO, GOSS, APLM, and CNTB

Should you buy NextCure stock or one of its competitors? NextCure's main competitors and comparable companies include PMV Pharmaceuticals (PMVP), OKYO Pharma (OKYO), Gossamer Bio (GOSS), Apollomics (APLM), and Connect Biopharma (CNTB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NextCure compare to PMV Pharmaceuticals?

PMV Pharmaceuticals (NASDAQ:PMVP) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

PMV Pharmaceuticals currently has a consensus target price of $4.33, suggesting a potential upside of 142.09%. NextCure has a consensus target price of $19.00, suggesting a potential upside of 273.28%. Given NextCure's higher probable upside, analysts plainly believe NextCure is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

PMV Pharmaceuticals has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, NextCure has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

In the previous week, PMV Pharmaceuticals had 1 more articles in the media than NextCure. MarketBeat recorded 2 mentions for PMV Pharmaceuticals and 1 mentions for NextCure. PMV Pharmaceuticals' average media sentiment score of 0.51 beat NextCure's score of 0.00 indicating that PMV Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PMV Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NextCure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

90.2% of PMV Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 10.2% of PMV Pharmaceuticals shares are owned by company insiders. Comparatively, 11.9% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PMV Pharmaceuticals' return on equity of -78.11% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-78.11%	-70.13%
NextCure	N/A	-154.62%	-100.19%

Summary

PMV Pharmaceuticals beats NextCure on 10 of the 14 factors compared between the two stocks.

How does NextCure compare to OKYO Pharma?

OKYO Pharma (NASDAQ:OKYO) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

OKYO Pharma presently has a consensus price target of $5.67, suggesting a potential upside of 285.49%. NextCure has a consensus price target of $19.00, suggesting a potential upside of 273.28%. Given OKYO Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe OKYO Pharma is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Comparatively, 11.9% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

OKYO Pharma's return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
NextCure	N/A	-154.62%	-100.19%

In the previous week, OKYO Pharma had 1 more articles in the media than NextCure. MarketBeat recorded 2 mentions for OKYO Pharma and 1 mentions for NextCure. OKYO Pharma's average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OKYO Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NextCure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

OKYO Pharma has a beta of 0.05, indicating that its stock price is 95% less volatile than the broader market. Comparatively, NextCure has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market.

Summary

OKYO Pharma beats NextCure on 8 of the 10 factors compared between the two stocks.

How does NextCure compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

NextCure has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
NextCure	N/A	-154.62%	-100.19%

In the previous week, Gossamer Bio had 3 more articles in the media than NextCure. MarketBeat recorded 4 mentions for Gossamer Bio and 1 mentions for NextCure. Gossamer Bio's average media sentiment score of 0.63 beat NextCure's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NextCure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gossamer Bio presently has a consensus target price of $256.00, suggesting a potential upside of 2,290.29%. NextCure has a consensus target price of $19.00, suggesting a potential upside of 273.28%. Given Gossamer Bio's higher possible upside, analysts clearly believe Gossamer Bio is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

NextCure has lower revenue, but higher earnings than Gossamer Bio. NextCure is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	1.35	-$170.37M	-$56.00	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 4.2% of Gossamer Bio shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Gossamer Bio has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, NextCure has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market.

Summary

Gossamer Bio beats NextCure on 9 of the 15 factors compared between the two stocks.

How does NextCure compare to Apollomics?

Apollomics (NASDAQ:APLM) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Apollomics has higher revenue and earnings than NextCure.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	8.10	-$10.94M	N/A	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

NextCure has a consensus price target of $19.00, suggesting a potential upside of 273.28%. Given NextCure's stronger consensus rating and higher possible upside, analysts clearly believe NextCure is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 11.9% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Apollomics' return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
NextCure	N/A	-154.62%	-100.19%

In the previous week, NextCure had 1 more articles in the media than Apollomics. MarketBeat recorded 1 mentions for NextCure and 0 mentions for Apollomics. Apollomics' average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score.

Company	Overall Sentiment
Apollomics	Neutral
NextCure	Neutral

Apollomics has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, NextCure has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

Summary

NextCure beats Apollomics on 6 of the 11 factors compared between the two stocks.

How does NextCure compare to Connect Biopharma?

Connect Biopharma (NASDAQ:CNTB) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 11.9% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NextCure's return on equity of -154.62% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-165.41%	-121.58%
NextCure	N/A	-154.62%	-100.19%

In the previous week, Connect Biopharma had 17 more articles in the media than NextCure. MarketBeat recorded 18 mentions for Connect Biopharma and 1 mentions for NextCure. Connect Biopharma's average media sentiment score of 0.19 beat NextCure's score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	5 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
NextCure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Connect Biopharma has higher revenue and earnings than NextCure. Connect Biopharma is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	972.89	-$55.48M	-$1.19	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

Connect Biopharma presently has a consensus target price of $6.14, indicating a potential upside of 562.66%. NextCure has a consensus target price of $19.00, indicating a potential upside of 273.28%. Given Connect Biopharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Connect Biopharma is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Connect Biopharma has a beta of -0.16, suggesting that its share price is 116% less volatile than the broader market. Comparatively, NextCure has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

Summary

Connect Biopharma beats NextCure on 10 of the 14 factors compared between the two stocks.

Get NextCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NXTC vs. The Competition

Export

Metric	NextCure	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.05M	$3.86B	$7.16B	$13.36B
Dividend Yield	N/A	3.65%	2.53%	17.32%
P/E Ratio	-0.57	13.05	274.85	26.18
Price / Sales	N/A	1,308.59	614.67	93.04
Price / Cash	N/A	39.04	27.22	34.70
Price / Book	0.50	17.17	11.25	6.40
Net Income	-$55.84M	-$23.20M	$3.50B	$381.35M
7 Day Performance	-1.57%	-2.52%	-1.57%	-0.45%
1 Month Performance	-36.06%	-10.24%	-5.91%	-4.34%
1 Year Performance	-12.82%	19.44%	7.98%	1.90%

NextCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
NXTC NextCure	2.7955 of 5 stars	$5.00 -1.8%	$19.00 +280.0%	-11.2%	$18.05M	N/A	N/A	40
PMVP PMV Pharmaceuticals	3.3378 of 5 stars	$1.43 +5.1%	$4.33 +203.0%	+24.3%	$72.70M	N/A	N/A	54
OKYO OKYO Pharma	2.1959 of 5 stars	$1.36 -0.7%	$5.67 +316.7%	-28.3%	$71.90M	N/A	N/A	5
GOSS Gossamer Bio	2.9495 of 5 stars	$11.58 +0.5%	$256.00 +2,110.7%	-94.8%	$70.39M	$48.47M	N/A	162
APLM Apollomics	1.6203 of 5 stars	$24.18 +1.4%	N/A	N/A	$69.51M	$8.50M	N/A	15

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NXTC) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NextCure (NXTC) Competitors

NXTC vs. PMVP, OKYO, GOSS, APLM, and CNTB

How does NextCure compare to PMV Pharmaceuticals?

Summary

How does NextCure compare to OKYO Pharma?

Summary

How does NextCure compare to Gossamer Bio?

Summary

How does NextCure compare to Apollomics?

Summary

How does NextCure compare to Connect Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC vs. The Competition

NextCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NextCure (NXTC) Competitors

NXTC vs. PMVP, OKYO, GOSS, APLM, and CNTB

How does NextCure compare to PMV Pharmaceuticals?

Do analysts rate PMVP or NXTC?

Which has more volatility & risk, PMVP or NXTC?

Does the media favor PMVP or NXTC?

Which has preferable valuation and earnings, PMVP or NXTC?

Do insiders & institutionals hold more shares of PMVP or NXTC?

Is PMVP or NXTC more profitable?

Summary

How does NextCure compare to OKYO Pharma?

Do analysts rate OKYO or NXTC?

Do insiders and institutionals have more ownership in OKYO or NXTC?

Is OKYO or NXTC more profitable?

Does the media prefer OKYO or NXTC?

Which has higher earnings & valuation, OKYO or NXTC?

Which has more volatility and risk, OKYO or NXTC?

Summary

How does NextCure compare to Gossamer Bio?

Is GOSS or NXTC more profitable?

Does the media favor GOSS or NXTC?

Do analysts recommend GOSS or NXTC?

Which has stronger valuation and earnings, GOSS or NXTC?

Do institutionals & insiders have more ownership in GOSS or NXTC?

Which has more risk and volatility, GOSS or NXTC?

Summary

How does NextCure compare to Apollomics?

Which has stronger earnings and valuation, APLM or NXTC?

Do analysts rate APLM or NXTC?

Do institutionals and insiders have more ownership in APLM or NXTC?

Is APLM or NXTC more profitable?

Does the media prefer APLM or NXTC?

Which has more risk and volatility, APLM or NXTC?

Summary

How does NextCure compare to Connect Biopharma?

Do institutionals and insiders hold more shares of CNTB or NXTC?

Is CNTB or NXTC more profitable?

Does the media favor CNTB or NXTC?

Which has better earnings & valuation, CNTB or NXTC?

Do analysts rate CNTB or NXTC?

Which has more risk and volatility, CNTB or NXTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC vs. The Competition

NextCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools